UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions

Pharmacology & therapeutics (Oxford), 2020-05, Vol.209, p.107503-107503, Article 107503

2020

Volltextzugriff (PDF)

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Diabetes care, 2015-01, Vol.38 (1), p.140-149

2015

Volltextzugriff (PDF)

Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes

Brain (London, England : 1878), 2020-10, Vol.143 (10), p.3067-3076

2020

Volltextzugriff (PDF)

Dipeptidyl peptidase-4 inhibition improves endothelial senescence by activating AMPK/SIRT1/Nrf2 signaling pathway

Biochemical pharmacology, 2020-07, Vol.177, p.113951-113951, Article 113951

2020

Volltextzugriff (PDF)

Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas

Diabetes, obesity & metabolism, 2016-04, Vol.18 (4), p.333-347

2016

Volltextzugriff (PDF)

Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans

Nature communications, 2020-07, Vol.11 (1), p.3766-12, Article 3766

2020

Volltextzugriff (PDF)

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

Circulation (New York, N.Y.), 2014-10, Vol.130 (18), p.1579-1588

2014

Volltextzugriff (PDF)

Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin

Diabetes care, 2015-03, Vol.38 (3), p.384-393

2015

Volltextzugriff (PDF)

SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management

Diabetes care, 2018-08, Vol.41 (8), p.1543-1556

2018

Volltextzugriff (PDF)

Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease

The New England journal of medicine, 2021-01, Vol.384 (1), p.11-19

2021

Volltextzugriff (PDF)

Food protein-derived bioactive peptides in management of type 2 diabetes

European Journal of Nutrition, 2015-09, Vol.54 (6), p.863-880

2015

Volltextzugriff (PDF)

Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38α, and NF-κB signaling

Toxicology and applied pharmacology, 2020-11, Vol.407, p.115246, Article 115246

2020

Volltextzugriff (PDF)

Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013

Diabetes care, 2017-04, Vol.40 (4), p.468-475

2017

Volltextzugriff (PDF)

Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population

Journal of investigative dermatology, 2019-04, Vol.139 (4), p.835-841

2019

Volltextzugriff (PDF)

Hypoglycemic peptide‐enriched hydrolysates of Corbicula fluminea and Chlorella sorokiniana possess synergistic hypoglycemic activity through inhibiting α‐glucosidase and dipeptidyl peptidase‐4 activity

Journal of the science of food and agriculture, 2022-01, Vol.102 (2), p.716-723

2022

Volltextzugriff (PDF)

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Diabetes care, 2017-01, Vol.40 (1), p.69-76

2017

Volltextzugriff (PDF)

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats

The Journal of pharmacology and experimental therapeutics, 2012-02, Vol.340 (2), p.248

2012

Volltextzugriff (PDF)

Incretin-based therapies for type 2 diabetes mellitus

Nature reviews. Endocrinology, 2009-05, Vol.5 (5), p.262-269

2009

Volltextzugriff (PDF)

Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial

World journal of gastroenterology : WJG, 2017-01, Vol.23 (1), p.141-150

2017

Volltextzugriff (PDF)

Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes

Diabetes care, 2017-02, Vol.40 (2), p.284-286

2017

Volltextzugriff (PDF)

Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes

JAMA dermatology (Chicago, Ill.), 2019-02, Vol.155 (2), p.172

2019

Volltextzugriff (PDF)

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Diabetes care, 2016-11, Vol.39 (11), p.2042-2050

2016

Volltextzugriff (PDF)

Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes

Journal of medicinal chemistry, 2019-03, Vol.62 (5), p.2348-2361

2019

Volltextzugriff (PDF)

Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

Drugs (New York, N.Y.), 2014-02, Vol.74 (2), p.223-242

Plosker, Greg L.

2014

Volltextzugriff (PDF)

Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes

Diabetes care, 2015-03, Vol.38 (3), p.394-402

2015

Volltextzugriff (PDF)

1 – 25 von 1.007

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(854)
Mit Volltextzugriff
(764)

Publikationsform

Artikel
(1.005)
magazinearticle
(2)

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(898)
Life Sciences & Biomedicine
(874)
Humans
(866)
Diabetes Mellitus, Type 2 - Drug Therapy
(687)
Dipeptidyl-Peptidase Iv Inhibitors - Administration & Dosage
(640)
Male
(622)
Female
(479)
Hypoglycemic Agents - Administration & Dosage
(472)
Middle Aged
(418)
Dipeptidyl-Peptidase Iv Inhibitors - Therapeutic Use
(369)
Diabetes
(361)
Endocrinology & Metabolism
(327)
Aged
(320)
Dipeptidyl-Peptidase Iv Inhibitors - Adverse Effects
(312)
Hypoglycemic Agents - Therapeutic Use
(291)
Pharmacology & Pharmacy
(286)
Type 2 Diabetes
(280)
Treatment Outcome
(260)
Diabetes Mellitus, Type 2 - Blood
(246)
Adult
(244)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes

Dipeptidyl peptidase-4 inhibition improves endothelial senescence by activating AMPK/SIRT1/Nrf2 signaling pathway

Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas

Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin

SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management

Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease

Food protein-derived bioactive peptides in management of type 2 diabetes

Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38α, and NF-κB signaling

Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013

Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population

Hypoglycemic peptide‐enriched hydrolysates of Corbicula fluminea and Chlorella sorokiniana possess synergistic hypoglycemic activity through inhibiting α‐glucosidase and dipeptidyl peptidase‐4 activity

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats

Incretin-based therapies for type 2 diabetes mellitus

Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial

Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes

Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes

Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes

Suchergebnisse filtern